174 related articles for article (PubMed ID: 18243921)
1. Iris morphology.
Teus MA; Arranz-Marquez E
Ophthalmology; 2008 Feb; 115(2):418-9; author reply 419-20. PubMed ID: 18243921
[No Abstract] [Full Text] [Related]
2. Morphometric effects of long-term exposure to latanoprost.
Cracknell KP; Grierson I; Hogg P
Ophthalmology; 2007 May; 114(5):938-48. PubMed ID: 17292473
[TBL] [Abstract][Full Text] [Related]
3. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change.
Grierson I; Lee WR; Albert DM
Arch Ophthalmol; 1999 Mar; 117(3):394-6. PubMed ID: 10088822
[No Abstract] [Full Text] [Related]
4. Evidence of early change in iris color with latanoprost use.
Pappas RM; Pusin S; Higginbotham EJ
Arch Ophthalmol; 1998 Aug; 116(8):1115-6. PubMed ID: 9715697
[No Abstract] [Full Text] [Related]
5. Histology and fine structure of the iris and outflow system following latanoprost therapy.
Grierson I; Pfeiffer N; Cracknell KP; Appleton P
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S176-84. PubMed ID: 12204715
[TBL] [Abstract][Full Text] [Related]
6. The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation.
Imesch PD; Wallow IH; Albert DM
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S117-23. PubMed ID: 9154287
[TBL] [Abstract][Full Text] [Related]
7. Mechanism and clinical significance of prostaglandin-induced iris pigmentation.
Stjernschantz JW; Albert DM; Hu DN; Drago F; Wistrand PJ
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S162-75. PubMed ID: 12204714
[TBL] [Abstract][Full Text] [Related]
8. Increased iris pigment in a child due to latanoprost.
Brown SM
Arch Ophthalmol; 1998 Dec; 116(12):1683-4. PubMed ID: 9869807
[No Abstract] [Full Text] [Related]
9. Analysis of irises with a latanoprost-induced change in iris color.
Arranz-Marquez E; Teus MA; Saornil MA; Mendez MC; Gil R
Am J Ophthalmol; 2004 Oct; 138(4):625-30. PubMed ID: 15488791
[TBL] [Abstract][Full Text] [Related]
10. Latanoprost-induced iris color darkening: a case report with long-term follow-up.
Camras CB; Neely DG; Weiss EL
J Glaucoma; 2000 Feb; 9(1):95-8. PubMed ID: 10708238
[TBL] [Abstract][Full Text] [Related]
11. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report.
Tsai JC; Sivak-Callcott JA; Haik BG; Zhang J; McLean IW
J Glaucoma; 2001 Oct; 10(5):411-3. PubMed ID: 11711840
[TBL] [Abstract][Full Text] [Related]
12. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.
Albert DM; Gangnon RE; Zimbric ML; Damico CM; Fisher MR; Gleiser J; Grossniklaus HE; Green WR
Arch Ophthalmol; 2004 Nov; 122(11):1680-5. PubMed ID: 15534130
[TBL] [Abstract][Full Text] [Related]
13. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.
Albert DM; Gangnon RE; Grossniklaus HE; Green WR; Darjatmoko S; Kulkarni AD
Arch Ophthalmol; 2008 May; 126(5):626-31. PubMed ID: 18474771
[TBL] [Abstract][Full Text] [Related]
14. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension.
Alm A; Grunden JW; Kwok KK
J Glaucoma; 2011; 20(4):215-22. PubMed ID: 20520568
[TBL] [Abstract][Full Text] [Related]
15. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study).
Pfeiffer N; Grierson I; Goldsmith H; Appleton P; Hochgesand D; Winkgen A
Arch Ophthalmol; 2003 Jan; 121(1):23-31. PubMed ID: 12523881
[TBL] [Abstract][Full Text] [Related]
16. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma.
Alm A; Schoenfelder J; McDermott J
Arch Ophthalmol; 2004 Jul; 122(7):957-65. PubMed ID: 15249358
[TBL] [Abstract][Full Text] [Related]
17. Monte Carlo simulation of latanoprost induced iris darkening.
Cracknell KP; Farnell DJ; Grierson I
Comput Methods Programs Biomed; 2007 Aug; 87(2):93-103. PubMed ID: 17576020
[TBL] [Abstract][Full Text] [Related]
18. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.
Wistrand PJ; Stjernschantz J; Olsson K
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S129-38. PubMed ID: 9154289
[TBL] [Abstract][Full Text] [Related]
19. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies.
Cracknell KP; Grierson I; Hogg P; Appleton P; Pfeiffer N
Exp Eye Res; 2003 Dec; 77(6):721-30. PubMed ID: 14609560
[TBL] [Abstract][Full Text] [Related]
20. Latanoprost and pigmentation.
Grierson I; Jonsson M; Cracknell K
Jpn J Ophthalmol; 2004; 48(6):602-12. PubMed ID: 15592791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
